ArticleScience progress

Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study.

Yifan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.